Literature DB >> 20162303

Transgenic zebrafish models of neurodegenerative diseases.

Jonathan J Sager1, Qing Bai, Edward A Burton.   

Abstract

Since the introduction of the zebrafish as a model for the study of vertebrate developmental biology, an extensive array of techniques for its experimental manipulation and analysis has been developed. Recently it has become apparent that these powerful methodologies might be deployed in order to elucidate the pathogenesis of human neurodegenerative diseases and to identify candidate therapeutic approaches. In this article, we consider evidence that the zebrafish central nervous system provides an appropriate setting in which to model human neurological disease and we review techniques and resources available for generating transgenic models. We then examine recent publications showing that appropriate phenotypes can be provoked in the zebrafish through transgenic manipulations analogous to genetic abnormalities known to cause human tauopathies, polyglutamine diseases or motor neuron degenerations. These studies show proof of concept that findings in zebrafish models can be applicable to the pathogenic mechanisms underlying human diseases. Consequently, the prospects for providing novel insights into neurodegenerative diseases by exploiting transgenic zebrafish models and discovery-driven approaches seem favorable.

Entities:  

Mesh:

Year:  2010        PMID: 20162303     DOI: 10.1007/s00429-009-0237-1

Source DB:  PubMed          Journal:  Brain Struct Funct        ISSN: 1863-2653            Impact factor:   3.270


  27 in total

Review 1.  Modeling human neurodegenerative diseases in transgenic systems.

Authors:  Miguel A Gama Sosa; Rita De Gasperi; Gregory A Elder
Journal:  Hum Genet       Date:  2011-12-14       Impact factor: 4.132

2.  Commentary: catching a conserved mechanism of ethanol teratogenicity.

Authors:  C Ben Lovely; Johann K Eberhart
Journal:  Alcohol Clin Exp Res       Date:  2014-08       Impact factor: 3.455

3.  A novel approach to study motor neurons from zebrafish embryos and larvae in culture.

Authors:  Stacey A Sakowski; J Simon Lunn; Angela S Busta; Madeline Palmer; James J Dowling; Eva L Feldman
Journal:  J Neurosci Methods       Date:  2012-01-20       Impact factor: 2.390

4.  Simple, economical heat-shock devices for zebrafish housing racks.

Authors:  Robert J Duszynski; Jacek Topczewski; Elizabeth E LeClair
Journal:  Zebrafish       Date:  2011-09-13       Impact factor: 1.985

5.  Human amyloidogenic light chain proteins result in cardiac dysfunction, cell death, and early mortality in zebrafish.

Authors:  Shikha Mishra; Jian Guan; Eva Plovie; David C Seldin; Lawreen H Connors; Giampaolo Merlini; Rodney H Falk; Calum A MacRae; Ronglih Liao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-04-26       Impact factor: 4.733

6.  Hypokinesia and reduced dopamine levels in zebrafish lacking β- and γ1-synucleins.

Authors:  Chiara Milanese; Jonathan J Sager; Qing Bai; Thomas C Farrell; Jason R Cannon; J Timothy Greenamyre; Edward A Burton
Journal:  J Biol Chem       Date:  2011-11-29       Impact factor: 5.157

7.  Major isoform of zebrafish P0 is a 23.5 kDa myelin glycoprotein expressed in selected white matter tracts of the central nervous system.

Authors:  Qing Bai; Ming Sun; Donna B Stolz; Edward A Burton
Journal:  J Comp Neurol       Date:  2011-06-01       Impact factor: 3.215

Review 8.  Nutritional Interventions for Mitochondrial OXPHOS Deficiencies: Mechanisms and Model Systems.

Authors:  Adam J Kuszak; Michael Graham Espey; Marni J Falk; Marissa A Holmbeck; Giovanni Manfredi; Gerald S Shadel; Hilary J Vernon; Zarazuela Zolkipli-Cunningham
Journal:  Annu Rev Pathol       Date:  2017-11-03       Impact factor: 23.472

9.  Can zebrafish be used as animal model to study Alzheimer's disease?

Authors:  Soraya Santana; Eduardo P Rico; Javier S Burgos
Journal:  Am J Neurodegener Dis       Date:  2012-05-15

Review 10.  Frontotemporal degeneration, the next therapeutic frontier: molecules and animal models for frontotemporal degeneration drug development.

Authors:  Adam L Boxer; Michael Gold; Edward Huey; Fen-Biao Gao; Edward A Burton; Tiffany Chow; Aimee Kao; Blair R Leavitt; Bruce Lamb; Megan Grether; David Knopman; Nigel J Cairns; Ian R Mackenzie; Laura Mitic; Erik D Roberson; Daniel Van Kammen; Marc Cantillon; Kathleen Zahs; Stephen Salloway; John Morris; Gary Tong; Howard Feldman; Howard Fillit; Susan Dickinson; Zaven Khachaturian; Margaret Sutherland; Robert Farese; Bruce L Miller; Jeffrey Cummings
Journal:  Alzheimers Dement       Date:  2012-10-05       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.